LifeMD Q2 revenue misses estimates as shift to branded GLP-1 therapies weighs

LifeMD

05/08/2026 21:56

Overview
US virtual care provider's Q2 revenue declined and missed analyst expectations
Q2 adjusted EBITDA loss widened and missed analyst estimates, but improved about 21% sequentially
Gross margin expanded to 89% on lower shipping and fulfillment costs, scaling in-house pharmacy

Outlook
LifeMD sees Q3 2026 revenue of $48 mln to $51 mln
Company expects Q3 2026 adjusted EBITDA between negative $1 mln and positive $2 mln
LifeMD revises 2026 revenue guidance to $205.5 mln-$212.5 mln, down from $220 mln-$230 mln

Result Drivers
SHIFT TO BRANDED GLP-1 - Co said transition from compounded to branded GLP-1 therapies reduced upfront revenue
GROSS MARGIN EXPANSION - Gross margin rose to 89% due to lower shipping and fulfillment costs and scaling of in-house pharmacy
SUBSCRIPTION BASE GROWTH - Active subscribers rose 20% year-over-year and Weight Management Program subscribers increased, supporting recurring revenue

Company press release: ID:nGNX9nS6lN

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$47.30 mln
$49.15 mln (8 Analysts)
Q2 Adjusted EBITDA
Miss
-$3.50 mln
-$340,500 (8 Analysts)
Q2 Gross Margin
 
89%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for LifeMD Inc is $10.00, about 156.4% above its August 4 closing price of $3.90

Reuters Recommended Reads
Aug 4 - Amwell Q2 revenue falls, co lifts low end of FY guidance 
Aug 5 - Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo
Aug 3 - Medifast Q2 revenue falls 28% as active coaches drop

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)